IN THE CLAIMS:

Please replace the present claim set with the following. Specifically, please amend claim 7 and cancel claims 78, 79, 84-91 and 98-103 as follows:

1 (original). A compound of Formula I:



Formula I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

A is C_{2-3} alkylene-$N(R_1)(R_2)$ or 1-(phenylmethyl)-pyrrolidin-3-yl;

R_1 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or

R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl,1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_mZ$,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and

m is 0 or 1.

2. (original) A compound according to claim 1 wherein R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form piperazinyl.
3. (original) The compound according to claim 2 which is 3-{3-[3-(4-pyrimidin-2-yl-piperazin-1-yl)-propoxy]-phenyl}-thieno[2,3-*d*]isoxazole.
4. (original) The compound according to claim 2 which is 3-{3-[3-(4-phenyl-piperazin-1-yl)-propoxy]-phenyl}-thieno[2,3-*d*]isoxazole.
5. (original) The compound according to claim 2 which is 3-(3-{3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-propoxy}-phenyl)-thieno[2,3-*d*]isoxazole.
6. (original) The compound according to claim 2 which is 3-(3-{3-[4-(2-fluoro-phenyl)-piperazin-1-yl]-propoxy}-phenyl)-thieno[2,3-*d*]isoxazole.
7. (currently amended) The compound according to claim 2 which is 3-{3-[2-(4-phenyl-piperazin-1-yl)-ethoxy]-phenyl}-thieno[2,3-d]isoxazole.
8. (original) A compound according to claim 1 wherein R_1 is indanyl.
9. (original) The compound according to claim 8 which is indan-2-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
10. (original) The compound according to claim 8 which is indan-1-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.
11. (original) The compound according to claim 8 which is indan-1-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
12. (original) The compound according to claim 8 which is indan-2-yl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.
13. (original) A compound according to claim 1, wherein R_1 and R_2 together with the nitrogen atom to which R_1 and R_2 are attached, form 1,2,3,4-tetrahydroisoquinolinyl.
14. (original) The compound according to claim 13 which is 2-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-1,2,3,4-tetrahydro-isoquinoline.
15. (original) The compound according to claim 13 which is 2-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-1,2,3,4-tetrahydro-isoquinoline.
16. (original) A compound according to claim 1 wherein R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form azepanyl.

17. (original) The compound according to claim 16 which is 3-[3-(2-azepan-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.

18. (original) A compound according to claim 1 wherein R_1 is adamantyl.

19. (original) The compound according to claim 18 which is adamantan-1-yl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

20. (original) The compound according to claim 18 which is adamantan-1-yl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

21. (original) A compound according to claim 1 wherein
Q is thienyl, phenyl, or pyridyl; or
R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form morpholinyl, piperidinyl, pyrrolidinyl , or azocanyl.

22. (original) The compound according to claim 21 which is 1-phenyl-2-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propylamino]-ethanol.

23. (original) The compound according to claim 21 which is 4-{2-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propylamino]-ethyl}-benzenesulfonamide.

24. (original) A compound according to claim 1 wherein A is
C_{2-3}alkylene-$N(R_1)(R_2)$;
R_1 is $(CH_2)nQ$;
n is 1;
R_2 is H;
Q is thienyl, phenyl, or pyridyl; or
R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form morpholinyl, piperidinyl, pyrrolidinyl , or azocanyl.

25. (original) The compound according to claim 24 wherein Q is thienyl.

26. (original) The compound of claim 25 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-thiophen-2-ylmethyl-amine.

27. (original) The compound of claim 25 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-thiophen-2-ylmethyl-amine.

28. (original) The compound of claim 25 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-thiophen-3-ylmethyl-amine.

29. (original) The compound of claim 25 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-thiophen-3-ylmethyl-amine

30. (original) A compound according to claim 24 wherein Q is phenyl.

31. (original) The compound according to claim 30 which is benzyl-[3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propyl]-amine.

32. (original) The compound of claim 30 which is benzyl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

33. (original) The compound of claim 30 which is (2-methoxy-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

34. (original) The compound of claim 30 which is (3-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

35. (original) The compound of claim 30 which is (2,6-difluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

36. (original) The compound of claim 30 which is (2,6-difluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

37. (original) The compound of claim 30 which is (2-fluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

38. (original) The compound of claim 30 which is (4-fluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

39. (original) The compound of claim 30 which is (4-chloro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

40. (original) The compound of claim 30 which is (4-methoxy-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

41. (original) The compound of claim 30 which is 4-{[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propylamino]-methyl}-benzenesulfonamide.

42. (original) The compound of claim 30 which is (4-chloro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

43. (original) The compound of claim 30 which is (4-methyl-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

44. (original) The compound of claim 30 which is (3,4-dichloro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

45. (original) The compound of claim 30 which is (2,4-difluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

46. (original) The compound of claim 30 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-(4-trifluoromethyl-benzyl)-amine.

47. (original) The compound of claim 30 which is (2-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

48. (original) The compound of claim 30 which is 2-chloro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

49. (original) The compound of claim 30 which is (3-methoxy-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

50. (original) The compound of claim 30 which is (3,4-difluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

51. (original) The compound of claim 30 which is (4-methyl-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

52. (original) The compound of claim 30 which is (2-chloro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

53. (original) The compound of claim 30 which is (3-methoxy-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

54. (original) The compound of claim 30 which is (3,4-difluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

55. (original) The compound of claim 30 which is (2,4-difluoro-benzyl)-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

56. (original) The compound of claim 30 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-(2-trifluoromethyl-benzyl)-amine.

57. (original) The compound of claim 30 which is [3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-(4-trifluoromethyl-benzyl)-amine.

58. (original) The compound of claim 30 which is (4-fluoro-benzyl)-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

59. (original) The compound of claim 30 which is [2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-(2-trifluoromethyl-benzyl)-amine.

60. (original) The compound of claim 30 which is benzyl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

61. (original) A compound according to claim 24 wherein Q is pyridyl.

62. (original) The compound of claim 61 which is pyridin-3-ylmethyl-[2-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-ethyl]-amine.

63. (original) The compound of claim 61 which is pyridin-3-ylmethyl-[3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propyl]-amine.

64. (original) A compound according to claim 24 wherein R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form piperidinyl.

65. (original) The compound according to claim 64 which is 3-[3-(3-piperidin-1-yl-propoxy)-phenyl]-thieno[2,3-*d*]isoxazole.

66. (original) The compound of claim 64 which is 3-{3-[2-(4-phenyl-piperidin-1-yl)-ethoxy]-phenyl}-thieno[2,3-*d*]isoxazole.

67. (original) The compound of claim 64 which is 3-[3-(2-piperidin-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.

68. (original) The compound of claim 64 which is 3-{3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-thieno[2,3-*d*]isoxazole.

69. (original) The compound of claim 64 which is 3-{3-[2-(4-propyl-piperidin-1-yl)-ethoxy]-phenyl}-thieno[2,3-*d*]isoxazole.

70. (original) A compound according to claim 24 wherein R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form pyrrolidinyl.

71. (original) The compound of claim 70 which is 3-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.

72. (original) A compound according to claim 24 wherein R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form azocanyl.

73. (original) The compound of claim 72 which is 3-[3-(2-azocan-1-yl-ethoxy)-phenyl]-thieno[2,3-*d*]isoxazole.

74. (original) A compound according to claim 24 wherein R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form morpholinyl.

75. (original) A compound according to claim 1 wherein A is 1-(phenylmethyl)-pyrrolidin-3-yl.

76. (original) The compound of claim 75 which is (S)-(+)-3-[3-(1-benzyl-pyrrolidin-3-yloxy)-phenyl]-thieno[2,3-*d*]isoxazole.

77. (original) The compound according to claim 75 which is (R)-(-)-3-[3-(1-benzyl-pyrrolidin-3-yloxy)-phenyl]-thieno[2,3-*d*]isoxazole.

78. (canceled) A method for antagonizing the effects of dopamine at the D_4 receptor comprising administering a compound according to claim 1 to a patient in need thereof.

79. (canceled) The method as defined in claim 78 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

80. (original) A composition comprising a compound according to claim 1 in admixture with an inert carrier.

81. (original) The composition according to claim 80 wherein said inert carrier is a pharmaceutical carrier.

82. (original) A method of treating psychoses comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

83. (original) The method as defined in claim 82 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

84. (canceled) A method of treating Attention Deficit Hyperactivity Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

85. (canceled) The method as defined in claim 84 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

86. (canceled) A method of treating Obsessive-Compulsive Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

87. (canceled) The method as defined in claim 86 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

88. (canceled) A method of treating Substance Abuse comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

89. (canceled) The method as defined in claim 88 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

90. (canceled) A method of treating Substance Dependence comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

91. (canceled) The method as defined in claim 90 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

92. (original) A method of treating Parkinson's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

93. (original) The method as defined in claim 92 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

94. (original) A method of treating Parkinsonism comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

95. (original) The method as defined in claim 94 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

96. (original) A method of treating Tardive Dyskinesia comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

97. (original) The method as defined in claim 96 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

98. (canceled) A method of treating Gilles de la Tourette Syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

99. (canceled) The method as defined in claim 98 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

100. (canceled) A method of treating Conduct Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

101. (canceled) The method as defined in claim 100 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

102. (canceled) A method of treating Oppositional Defiant Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

103. (canceled) The method as defined in claim 102 wherein the compound is (3-fluoro-benzyl)-[2-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-ethyl]-amine.

104. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof,
wherein

A is C_{2-3} alkylene-$N(R_1)(R_2)$;

R_1 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and
Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and
n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or

R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl,1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_mZ$,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and

m is 0 or 1;

comprising the step coupling a reagent of formula II



II

wherein

X is Br, Cl or I; and

p is 2 or 3;

with a reagent of formula III



III

wherein R_1 and R_2 are defined as in formula I;

to provide a compound of formula I.

105. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof.

wherein

A is 1-(phenylmethyl)-pyrrolidin-3-yl;

comprising the step of coupling a reagent of formula II



II

with a reagent of formula III



III

to provide the compound of formula I.

106. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof,
wherein

A is C_{2-3} alkylene-$N(R_1)(R_2)$;

R_1 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or

R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl,1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_mZ$,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and

m is 0 or 1;

comprising the step of coupling a reagent of formula II



II

with a reagent of formula III



III

wherein

R_1, and R_2 are defined as in formula I;

p is 2 or 3; and

Y is Br, Cl, I, aryl sulfonate or alkyl sulfonate;

to provide the compound of formula I.

107. (original) A method of making a compound of Formula I:



I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

A is C_{2-3} alkylene-$N(R_1)(R_2)$;

R_1 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or

R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl,1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_mZ$,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and

m is 0 or 1;

comprising the step of reducing a compound of the formula



II

wherein p is 1 or 2; and

R_1 and R_2 are as defined in formula I;

to provide a compound of formula I.

108. (original) A compound of formula



wherein

p is 1 or 2; and

R_1 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, phenyl, furanyl, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl; and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2;

R_2 is H or C_{1-6} alkyl; or

R_1 and R_2, together with the nitrogen atom to which R_1 and R_2 are attached, form 4,5,6,7-tetrahydrothieno [3,2-c] pyridinyl,1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, azepanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1H-β-carbolinyl, or 8-aza-bicyclo[3.2.1.]octanyl, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_mZ$,

Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzthienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and

Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and

m is 0 or 1.

109. (original) A compound of formula



wherein X is Br, Cl or I; and
p is 2 or 3.